Cargando…
The E2F4 prognostic signature predicts pathological response to neoadjuvant chemotherapy in breast cancer patients
BACKGROUND: Neoadjuvant chemotherapy is a key component of breast cancer treatment regimens and pathologic complete response to this therapy varies among patients. This is presumably due to differences in the molecular mechanisms that underlie each tumor’s disease pathology. Developing genomic clini...
Autores principales: | Mark, Kenneth M. K., Varn, Frederick S., Ung, Matthew H., Qian, Feng, Cheng, Chao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5414335/ https://www.ncbi.nlm.nih.gov/pubmed/28464832 http://dx.doi.org/10.1186/s12885-017-3297-2 |
Ejemplares similares
-
Whole Transcriptome Signature for Prognostic Prediction (WTSPP): application of whole transcriptome signature for prognostic prediction in cancer
por: Schaafsma, Evelien, et al.
Publicado: (2020) -
Regulators Associated with Clinical Outcomes Revealed by DNA Methylation Data in Breast Cancer
por: Ung, Matthew H., et al.
Publicado: (2015) -
The E2F4 prognostic signature is also predictive of the pathological response of breast cancer to chemotherapy
por: Bertucci, François, et al.
Publicado: (2015) -
Integrative analysis of survival-associated gene sets in breast cancer
por: Varn, Frederick S, et al.
Publicado: (2015) -
Tumor Microenvironment Characterization in Breast Cancer Identifies Prognostic and Neoadjuvant Chemotherapy Relevant Signatures
por: Ji, Fei, et al.
Publicado: (2021)